Biotechnology

Biovie

Biovie released FY2026 Q1 earnings on November 10 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.984 (forecast USD -0.79)

Biovie released FY2025 Annual Earnings on August 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -12.1239 (forecast USD -11.4)

Biovie released FY2025 Q4 earnings on August 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.8774 (forecast USD -3.6)

BioVie Inc. drug bezisterim shows progress in treating Alzheimer's and Parkinson's

BioVie to Present SUNRISE-PD Trial at Advanced Therapies for Movement & Related Disorders Congress

BioVie to Host KOL Event for Bezisterim Parkinson's Disease Study

Biovie released FY2025 Q3 earnings on May 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.5066 (forecast USD -3.2)

Biovie released FY2025 9 Months Earnings on May 12 (EST), actual revenue USD 0, actual EPS USD -13.1066

BioVie Initiates Clinical Trial for BEZISTERIM to Evaluate Parkinson's Disease Treatment

Biovie released FY2025 Q2 earnings on February 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -4.6 (forecast USD -16)

Biovie released FY2025 Semi-Annual earnings on February 11 (EST), actual revenue USD 0, actual EPS USD -10.5353

Biovie released FY2025 Q1 earnings on November 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -7 (forecast USD -16)

Biovie released FY2024 Q4 earnings on September 30 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -8.3039 (forecast USD -15)

Biovie released FY2024 annual earnings on September 30 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -73.05 (forecast USD -118)

Proposed Public Offering by BioVie

BioVie Receives FDA Approval for Phase II Clinical Trial of BEZISTERIM

BioVie Company Resumes Compliance with NASDAQ Listing Rules

Biovie announces agreement with FDA on assessment of Bezisterim consistency in Parkinson's disease clinical trials

BioVie announces stock consolidation

Biovie released FY2024 9 Months Earnings on May 14 (EST) with actual revenue of USD 0 and EPS of USD -71.2101

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap